Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV001280047 | SCV002814863 | uncertain significance | Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 | 2022-05-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002542941 | SCV003284477 | uncertain significance | not provided | 2022-07-23 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 400 of the GFM1 protein (p.Arg400Cys). This variant is present in population databases (rs374335959, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with GFM1-related conditions. ClinVar contains an entry for this variant (Variation ID: 991779). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C65"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001280047 | SCV001467194 | uncertain significance | Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 | 2020-08-14 | no assertion criteria provided | clinical testing |